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Abstract
Isoniazid (INH), one of two first-line drugs used to treat tuberculosis (TB), has been shown to be a potent inhibitor of InhA, the mycobacterial enoyl reductase. However, the increasing resistance to INH makes it imperative to
find alternative drugs that are as effective as the first-line drugs, yet active against INH-resistant strains. Since InhA
has been validated as an excellent target of TB, there have been attempts to find novel inhibitors of InhA.Through
rational drug design, a variety of high affinity InhA inhibitors were synthesized.Triclosan itself was observed to be a
suboptimal inhibitor of InhA with a K of .22 µM, but with modifications to the 5-position of the A ring, the new diphenyl ether compounds demonstrated higher affinities with nanomolar constants. A particularly potent triclosan
derivative, compound PT70, showed slow, tight-binding inhibition with a K value of 22 pM. In addition, arylamides
showed moderate to high inhibition of InhA. They did not show sufficient anti-tubercular activity, and therefore
future modifications are needed before they can be considered seriously for use against TB. Lastly, pyridomycin,
a natural anti-tubercular drug was rediscovered and confirmed to have high activity against TB. It was found to
be the first compound ever published to bind to both binding sites of InhA simultaneously. Current research is
ongoing in the synthesis and testing of pyridomycin analogs to further increase their anti-tubercular properties.
Introduction

Drug resistance in Mycobacterium tuberculosis (TB) has become
a severe global health threat.The fight against TB faces major challenges due to the appearance of Multi-Drug Resistant Tuberculosis
(MDR-TB) and more recently, the virtually untreatable Extensively
Drug Resistant Tuberculosis (XDR-TB). MDR-TB are strains that
are resistant to both top first-line drugs, Isoniazid and Rifampin,
while XDR-TB are MDR-TB strains that are also resistant to any
fluoroquinolone and one or more of 3 injectable drugs. With this
new resistance there emerges a need to find new drugs that are
as effective yet bypass the problem of resistance. One method
of research is to find new vulnerabilities of M. tuberculosis to
use as new target sites of drugs. This method is highly expensive
and requires intense and lengthy research just to implicate a new
target site (Scheffler et al., 2013). An alternative is to develop new
drugs that work on the same known targets as the first-line drugs
but by different mechanisms thereby bypassing the resistance of
TB to the drug.
Isoniazid (INH) is a powerful anti-TB drug that works by inhibiting
the action of InhA, a crucial enzyme in the process of manufacturing the cell wall. Instead of searching for new targets on TB, there
is a goal to expand on this target and develop drugs that inhibit
InhA by different mechanisms and thus show anti-tubercular activity against MDR-TB strains.
The virulence of tuberculosis is due to its greatly complex cell
envelope. Mycobacteria contain cell walls with unusually high lipid
content due mainly to the presence of mycolic acids which are

alpha-alkyl, beta-hydroxy fatty acids with atypically long alpha alkyl
chains (up to C ). The existence of mycolic acids in the cell wall
makes the cell impervious to common antibiotics (Niederweis et
al., 2010). Mycolic acids were shown to be essential for the survival of tuberculosis thereby making them a great target for drug
therapy. InhA (NADH-dependent-2-trans-enoyl-ACP-reductase)’s
role in mycolic acid biosynthesis is catalyzing the final step in a
cycle of elongation by reducing 2-trans-enoyl chains to their saturated forms (Takayama et al., 2005).
Isoniazid (INH) has been used to treat tuberculosis since 1952. It
is a prodrug that enters cells via passive diffusion where is it then
converted from an inactive nontoxic form to its active toxic form.
This conversion is mediated by KatG, a mycobacterial multi-functional catalase-peroxidase that activates INH by peroxidation to
form a variety of intracellular INH-derived radical species.The key
intermediate in this reaction is the isonicotinoyl radical (Figure 1,
compound 3) which then covalently binds to coenzyme NAD+
to generate an isonicotinoyl-NAD adduct (INH-NAD) (Timmins,
Deretic, 2006). The addition of the isonicotinoyl radical to NAD+
creates a stereocenter in the INH-NAD adduct, and it is the acyclic 4S isomer that selectively binds to InhA as a slow tight-binding
competitive inhibitor (K = 0.75 nM) (Rozwarski et al., 1998; Rawat
et al., 2003). The binding of the INH-NAD adduct inhibits InhA
from taking part in mycolic acid biosynthesis leading to impaired
cell wall integrity and eventual cell death.
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is then used to predict how similar synthesized compounds may
interact with the target. Additionally, the 3D structure of a target
molecule both alone and in complex with the synthesized compounds is frequently obtained through X-ray crystallography and
NMR spectroscopy to determine the underlying basis for the efficacy (or lack thereof) of the newly synthesized compounds.

Figure 1
Structures of isoniazid (1), the isonicotinic hydrazyl radical (2) and the
isonicotinoyl radical (3) Timmins, Deretic, 2006

Despite its powerful anti-TB potential, the foremost problem with
INH is the increasing resistance to the drug. In fact, INH resistance
is the most common type of drug-resistant TB. The predominant
mechanism of such resistance involves a single point mutation in
the gene that codes for the KatG enzyme which results in an
amino acid change from serine to asparagine at position 315 in the
heme binding catalytic domain of KatG (Zhang, Yew, 2009). This
S315T mutant is observed to contain a narrower heme access
channel on KatG (4.7 Å compared to the wild type 6 Å) suggesting that the loss of INH access to the oxidizing site of KatG might
be the key to INH-resistance (Timmins, Deretic, 2006). While
isolates with this mutation completely lose the ability to form
the INH-NAD adducts, most retain good catalase activity and are
therefore able to survive despite the mutation (Gumbo, 2011).
Less commonly, resistance is also seen to occur by mutations in
the promoter region of the InhA gene, leading to overexpression
of InhA; or by mutations at the active site of InhA, resulting in
lower InhA affinity to the INH-NAD adduct (Zhang,Yew, 2009).
There are many methods of drug development. Older methods
rely on trial and error testing of chemical substances on cells or
whole organisms. This method is extremely lengthy and expensive
as it requires the screening of hundreds of thousands of compounds for activity. A newer method called rational drug design
employs prior detailed knowledge of a vulnerable target and its
three-dimensional structure to synthesize biologically active compounds that specifically interact with the target. One manner of
rational drug design is structure-based drug design, which employs
the principle of SAR (Structure-Activity Relationship) that theorizes that similarly structured molecules have similar activities.
Thus, if a compound is known to possess a desired activity, the
essential functional groups and moieties responsible for this activity can be identified and a variety of new compounds containing
those groups can be synthesized. The new compounds will then
be tested for efficacy and functional similarity to the parent compound. SAR commonly employs the use of molecular mechanics/
dynamics software to analyze and predict the conformations of
known molecules and to subsequently model the conformational
changes that occur in a bound target molecule. This information
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In the following literature review, a variety of SAR studies that
attempted to find novel InhA inhibitors are summarized. The majority of the compounds discussed used a backbone of the biocide
triclosan to create triclosan derivatives and substituted diphenyl
ethers that exhibit InhA inhibition as well as efficacy against a
variety of tuberculosis strains. Additionally, arylamide moieties
have been confirmed as good InhA inhibitors although additional
research is still needed to improve their anti-tubercular activity.
Lastly, pyridomycin, a natural anti-Mycobacterial drug was recently
rediscovered and shown to be effective against multiple strains of
TB, as well as showing inhibition of InhA in a unique manner.

Methods

Literature searches were performed using the Touro College
Online Library. In particular, the Health Sciences related databases
(Medline, PubMed, Proquest Medical Library (Health and Medical
Complete), and EBSCO Multisearch were employed. Additionally,
Google Scholar and the Touro Quicksearch option proved to be
very helpful in finding the necessary relevant articles. The following keywords were searched: Mycobacteria, tuberculosis, InhA
inhibitors, triclosan, triclosan derivatives, high affinity InhA inhibitors, SAR, rational drug design, arylamides, pyridomycin. As a final
point, only articles published in scholarly peer-reviewed journals
after the year 2005 were included in the search.

Results and Discussion

Triclosan derivatives and diphenyl ethers
The biocide triclosan (Figure 2), originally thought to have nonspecific antimicrobial activity, has been shown to target and uncompetitively inhibit enoyl reductases, the family of enzymes that
includes InhA (Heath et al., 2001). Consistent with uncompetitive
inhibition, triclosan binds to the enoyl reductases in the presence
of NAD+. Triclosan is an excellent inhibitor of the E. coli enoyl
reductase FabI with a picomolar inhibition constant (K = 7 pM)
but is shown to be only a submicromolar inhibitor (K = 0.2 µM)
of InhA (Ward et al., 1999). To understand the 30,000 fold difference in triclosan’s affinity for FabI versus InhA, crystal structures
of FabI in complex with NAD+ and triclosan were compared to
structures of InhA in complex with NAD+ and triclosan, so as to
compare the ligand bindings and use the information to develop
new inhibitors with high affinity for InhA (Sullivan et al., 2006).
The structures of triclosan bound to FabI and to InhA were generally very similar yet an important difference was seen with respect
to the ordering of the amino acid loop that covers the substrate
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Figure 2:
Molecular structure of triclosan Sullivan et al., 2006

Figure 3
Modified diphenyl ether inhibitors Sullivan et al., 2006

binding site of each enzyme. In the FabI:NAD:triclosan molecule,
the substrate binding loop (residues 195-200) is ordered when
triclosan is bound to it. In contrast, the substrate binding loop of
InhA (residues 197-210) is disordered when triclosan binds to it. It
has been suggested that ordering of the loop is indicative of slow,
tight binding inhibition (Heath et al., 2001). When the substrate
binding loop becomes structured, additional Van der Waals interactions strengthen the binding.A key feature of slow-binding inhibitors is a conformational change in the enzyme upon drug binding.
This is likely the slow step in the reaction, a hypothesis that is supported by the fact that triclosan has been identified as a slow, tight
binding inhibitor of FabI but not InhA. Since slow-order kinetics
has not been determined in the inhibition of InhA by triclosan, the
loop is disordered in InhA (Sullivan et al., 2006). Ordering of the
loop has been observed in the inhibition of InhA by the INH-NAD
adduct, which has also been identified as a tight-binding inhibitor
of InhA (Rawat et al., 2003), further supporting the hypothesis that
connects slow, tight-binding inhibition to ordering of the active
site loop.

binding loop which led to the observed significant increase in inhibitory activity. In addition to lower IC values, the alkyl diphenyl
ethers showed significantly lower MIC (minimum inhibitory concentration) values than triclosan (MIC 6.5µM vs. 43.1µM) against
drug sensitive TB (H37Rv strain) as well as 5 INH resistant strains,
thus demonstrating their potential for use against MDR-TB and
validating the hypothesis that compounds that do not require activation by KatG will be active against most INH resistant strains
of TB.The results of this study revealed that the reason for the differences in triclosan’s inhibition of FabI and InhA is that InhA has
a large substrate binding loop that triclosan cannot fill as entirely
as it can the smaller active site of FabI. Substituting alkyl chains
on the triclosan molecule thus allowed for more hydrophobic interactions deeper into the binding site and consequently higher
affinity was demonstrated for InhA. Testing of the alkyl diphenyl
ethers on H37Rv and 5 INH resistant strains confirmed that this
higher affinity also led to greater anti-tubercular activity (Sullivan
et al., 2006).

Comparison of FabI and InhA crystal structures showed that InhA
contains a larger substrate binding loop than FabI (14 residues vs.
6 residues), making it harder to order the loop in InhA. Sullivan et
al. hypothesized that longer substituents on the diphenyl ether A
ring of triclosan might result in additional hydrophobic contacts
between triclosan and the substrate binding pocket residues, and
thereby increase the affinity for InhA. They removed the chlorine
atoms from the B ring and substituted the chlorine atom on the A
ring with alkyl groups of varying length (Figure 3).
As the length of the alkyl substituents increased from 2 carbons to
8 carbons, the IC value (the concentration of inhibitor needed to
inhibit 50% of the enzymes) decreased significantly from 2 µM to
5 nM, indicating considerably higher affinity for InhA. In each case,
the compounds were rapid, reversible uncompetitive inhibitors
like the parent molecule triclosan.The most potent diphenyl ether,
which was identified as 5-octyl-2-phenoxyphenol (8PP), displayed
an IC of 5 nM (K =1.1 nM).The octyl chain in this molecule adopted a linear confirmation and burrowed into the pocket, forming
numerous hydrophobic interactions with residues in the substrate

Treatment of TB is lengthy (6-24 months), so toxicity is a significant concern in the development of potential anti-tubercular
drugs. The two most potent inhibitors identified by Sullivan et al.,
6PP and 8PP, were tested using a Vero cell line and shown to be
five times less toxic than triclosan with a therapeutic index of 5-6
compared to <1 for triclosan. Treatment with triclosan at 1xMIC
for one day proved lethal to the cells. Furthermore, TB-infected
macrophages treated with 2xMIC of 6PP and 8PP demonstrated
high level growth inhibition, indicating an ability of these drugs
to enter macrophages and remain effective against intracellular
tuberculosis growth. Oral administration of 6PP and 8PP in mice
also showed no adverse effects, substantiating a lower toxicity
for these molecules.These studies demonstrated that alkyl substituted diphenyl ethers exhibited lower toxicity towards cells and
TB-infected macrophages than did triclosan (Boyne et al., 2007).
While 6PP and 8PP showed high potency against InhA (nM inhibition constants) and improved efficacy against both drug-sensitive
and drug-resistant strains, they were observed to have low bioavailability with significantly high cLogP (partition coefficient) values (6PP= 6.47). The clogP value is important for predicting oral
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Table 1

Inhibition and solubility data for modified B ring heterocycles

Compound

Structure

IC5((nM)

MIC (µg/ml)

ClogP

LogP

19 (6PP)

11 ± 1

2.1 ± 0.9

6.47

5.76

3c

160 ± 16

3.13

4.97

4.93

14a

62 ± 5

3.13

5.24

14b

1090 ± 90

100 ± 0

14c

55 ± 6

12.50

5.24

5.24

5.27

4.93

amEnde et al., 2008

absorption as it relates to a compound’s solubility and ability to
permeate through cell membranes. Compounds that are too hydrophilic (low cLogP) are not able to pass through the hydrophobic membranes, while compounds that are too hydrophobic (high
cLogP) tend to be insoluble and have trouble permeating through
membranes because they can get stuck in the hydrophobic bilayer.
In general, a cLogP greater than 5 predicts poor absorption or
permeation (Lipinski et al., 2001).
To lower the cLogP values, modifications were made to the B
ring of the diphenyl ether backbone of 6PP. A series of analogs
that incorporated different functional groups on the ring, designed
to increase the polarity of the alkyl diphenyl ethers, were synthesized. Two series were made: one series replaced the B ring
with isosteric heterocycles that incorporated nitrogen atoms into
the ring to increase polarity without added steric strain while the
other series incorporated polar bulky substituents at different positions on the B ring. The results were primarily stereoselective.
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Overall, the addition of bulky substituents at either ortho, meta,
or para positions of the B ring and the incorporation of most nitrogen heterocycles caused significantly higher MIC values and reduced inhibitory activity. However, the addition of nitro or amino
substituents at ortho/para positions only slightly reduced inhibitory activity. While none of the newly synthesized compounds
showed IC or MIC values lower than the parent compound 6PP,
compounds 3c and 14a (Table 1) had inhibitory values similar to
6PP but also had lower cLogP values (4.97 and 5.24 respectively).
The results demonstrate that the addition of nitrogen containing
compounds at certain positions on the B ring can lower the hydrophobicity of the compounds. Additional studies are needed to
test whether the modifications result in increased bioavailability
and improved in vivo antibacterial activity (amEnde et al., 2008).
InhA has two hydrophobic cavities that are capable of being filled:
the hydrophobic substrate binding pocket in which the substrate
of InhA (2-trans-dodecenoyl-CoA) binds, and the NADH binding

Novel inhibitors of InhA

compound 10 (Freundlich et al., 2009).

Figure 4:
Cross-section of the InhA active site with superimposed structures of InhA in
complex with the INH-NAD adduct (colored in gold) and triclosan (white).
The A ring chlorine of triclosan (cyan) is observed to be very close to the
isonicotinoyl binding site. Freundlich et al., 2009

active site. The NADH active site sits underneath the substrate
binding pocket and is lined primarily with hydrophobic residues.
Most InhA inhibitors, including triclosan and its derivatives, inhibit
InhA through binding to the substrate binding pocket.The competitive inhibitor INH-NAD adduct, is one of the few inhibitors that
binds directly to the NADH active site. Freundlich et al., (2009)
observed the structure of InhA:NAD+:triclosan superimposed on
InhA:INH:NAD and saw that the chlorine atom at position 5 of
the triclosan A ring was only 2 Å from the binding pocket of the
isonicotinoyl moiety of the INH-NAD adduct (Figure 4). They hypothesized that triclosan derivatives can be synthesized that can
extend into the hydrophobic isonicotinoyl binding pocket and increase inhibition of InhA by occupying both the substrate binding
pocket and the NADH binding site. This hypothesis was different
than Sullivan et al. (2006) who created analogs to increase interactions with the substrate binding loop, mimicking the structure
of the substrate.
The analogs of Freundlich et al., were similar to those of Sullivan
et al., but differed in that a variety of both hydrophobic and hydrophilic substituents were added to position 5 on the A ring.
Additionally, contrary to the previous studies of Sullivan et al., it
was suggested that the two chlorine atoms on the B ring do in fact
participate in hydrophobic interactions with Phe97 and Met103
residues and so they remained in the compounds. The results
showed that the compounds with alkyl (hydrophobic) substituents were the more potent inhibitors. As seen with Sullivan et
al., inhibition of InhA increased with increasing alkyl chain length.
The highest inhibitory potencies for the alkyl chain additions were
observed in the 4 carbon chain compounds (Table 2), namely

Surprisingly, while most hydrophobic substituents were observed
to show lower IC values, the addition of a phenyl group at the 5
position (Compound 6) showed a much greater IC (IC >10,000
nM) than even triclosan (IC =1,100 nM). The same values were
obtained for a pyridyl group at the 5 position. Modeling the inhibitors in the active site showed that the aryl group was too far from
the isonicotinoyl binding pocket by 2.5 Å and was also positioned
too close to Phe149 which led to steric clashes. Therefore, to
better fit the phenyl group into the hydrophobic pocket, a carbon
linker chain consisting of 1-3 carbons was added to the 5 position
(Compounds 24-26) between the phenyl group and the A ring.
This resulted in significantly increased inhibitory potency of the
phenyl substituted compounds (IC of 21-51 nM). Compound 25,
with a 2 carbon linker chain showed the lowest IC of all the compounds tested with a measured potency 50 times that of triclosan.
Adding linkers to the pyridyl substituents (Compunds 17-19) also
proved effective in producing powerful inhibitors (IC of 29-75
nM).
Through analysis of crystal structures, it became apparent that the
goal of mimicking the isonicotinoyl moiety and reaching the isonicotinoyl binding site was not possible. The triclosan derivatives
did reach the isonicotinoyl binding site but they did not occupy
the same volume as the INH-NAD adduct. Instead, their actions
mimicked the substrate analogs like Sullivan et al.’s compounds
did. Attempts to increase the volume of the triclosan analogs in
order to mimic the isonicotinoyl moiety would cause a rotation
of Phe149, which in turn would displace Tyr158 and result in the
loss of a crucial hydrogen bond, leading to the complete loss of
inhibitor binding. Therefore, it was concluded that triclosan derivatives can only attempt to place their substituents near the binding pocket and increase hydrophobic interactions in a way that
mimics the substrate rather than the isonicotinoyl-NAD adduct
(Freundlich et al., 2009).
Six of Freundlich et al.’s compounds (three alkyl and three aryl
with IC < 110 nM) were tested for anti-tubercular activity. All of
the compounds were more active than triclosan against H37Rv
strain (wild type). Additionally, all showed high inhibition against
five INH resistant strains demonstrating their potential for use in
treatment against MDR-TB. These results revealed that while triclosan analogs cannot be used to mimic the INH-NAD adduct in
the isonicotinoyl binding pocket they can act as substrate analogs.
The aryl and pyridyl substituents with carbon chain linkers as well
as many straight chain substituents showed considerably lower
IC values than triclosan, displaying higher affinity for InhA. They
also showed greater anti-tubercular activity than triclosan when
tested against both drug-sensitive and drug-resistant tuberculosis
(Freundlich et al., 2009).
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Table 2

In vitro activities of select triclosan derivatives against InhA

Compound

R1

R2

Triclosan

Cl

Cl

6

Ph

Cl

>10000

10

(CH2)3 CH3

Cl

55 ± 20

14

2-pyridyl

CN

>10000

15

3-pyridyl

Cl

>10000

16

4-pyridyl

CN

>10000

17

CH2 (2-pyridyl)

Cl

18

CH2 (3-pyridyl)

Cl

19

CH2 (4-pyridyl)

CN

24

CH2 Ph

Cl

25

(CH2)2 Ph

Cl

26

(CH2)3 Ph

Cl

Feundlich et al., 2009
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InhA IC5(nM)
1100 ± 180

29 ± 11
42 ± 10
75 ± 16
51 ± 6
21 ± 8
50 ± 14
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using the hypothesis that compounds with the ability to order
the loop will be slow tight-binding inhibitors of InhA. They used
Sullivan et al.’s 6PP analog as a backbone and introduced a variety
of groups onto the B ring in the hopes of promoting increased
hydrophobic interactions between the inhibitor and the loop
residues.

Figure 5
Addition of a methyl group on the ortho position of the B ring of 6PP led to
PT70, a slow onset, tight binding diphenyl ether inhibitor. Luckner et al., 2010

One resulting compound, PT70 (Figure 5), contained a methyl
group ortho to the diphenyl ether linkage and showed a substantially higher affinity for InhA, with a K of 22 pM, a value 430-fold
lower than that of 6PP (K =9.4 nM). Additionally, PT70 displayed
slow-onset inhibition which is essential for in vivo antibacterial
activity. Crystal structures of InhA:NAD+:PT70 showed that PT70
binds to InhA in almost the same way that triclosan and its derivatives do. The main difference in the binding is that the methyl
group on PT70 generates additional hydrophobic interactions
with Ala198, Met199, Ile202 and Val203 residues on the substrate
binding loop, leading to a defined loop structure (Figure 6). The

One problem with the triclosan derivatives and diphenyl ethers
thus far is that they are shown to be rapid reversible inhibitors of
InhA. An important and vital factor of in vivo drug activity is long
residence times on the targets. Furthermore, structures of the
previous compounds had indicated a disordered substrate binding
loop. It had earlier been theorized that slow onset inhibition is
coupled with ordering of an active site loop, which leads to the
closure of the substrate binding pocket. Luckner et al., (2010) attempted to create a slow onset triclosan-derived inhibitor of InhA

Figure 7
Scaffold of He et al.’s arylamides He et al., 2007

Figure 6
Loop ordering is observed upon slow binding inhibition. A) InhA•NAD+•8PP complex in the binding of 8PP (Sullivan et al.’s most potent inhibitor) to InhA. NAD+
is displayed in cyan and the 8PP molecule is in black.The substrate-binding loop is disordered in the 8PP structure, and the loop ends are depicted in red. B)
InhA•NAD+•PT70 complex.The PT70 compound is depicted in black.The substrate-binding loop (shown in red) is ordered in this structure and covers the binding
pocket. Luckner et al., 2010
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ordered binding loop covers the entrance to the binding pocket
locking PT70 inside and increases the residence time on the target. Kinetic data show that PT70 has a residence time of 24 minutes on the target, a 14,000 fold increase over the residence time
of its parent compound 6PP (0.1 sec). This study also confirmed
the hypothesis that ordering of the active site loop is coupled to
slow-onset inhibition. Further research is needed to test PT70
on tuberculosis strains to confirm that the increase in affinity of
PT70 for InhA does indeed correlate with enhanced anti-bacterial
activity (Luckner et al., 2010).

Triclosan has been recognized as a great molecular scaffold for
InhA inhibition. The previous studies all employed the diphenyl
ether backbone of triclosan. Modifications to both the A and B
ring demonstrated increased affinity for InhA which was also
coupled to greater anti-tubercular activity. The compounds show
tremendous promise for rational drug design and SAR use in the
treatment of TB. Significantly, it was confirmed that these compounds do not require KatG activation affording them great
potential against the most common strains of drug-resistant TB.
Further research is still needed to test the compounds in vivo to
confirm their anti-tubercular capacity.

Arylamides

Figure 8
a) Inhibitor b3 bound to the active site of InhA. As illustrated, extra space
is observed in the area below the B ring of the inhibitor b) Details of the
InhA-b3 interactions. Relevant residues of the binding pocket are shown.The
amide oxygen hydrogen-bonds with the 2`-hydroxyl moiety of the nicotinamide
ribose and the hydroxyl group of Tyr158 (blue arrows). He et al., 2007

Arylamides (Figure 7) have also been identified as a potential scaffold of InhA inhibitors. Using High Throughput Screening (HTS),
He et al., (2007) identified a variety of arylamides all of which
contained either a piperazine or piperidine compound as the core
structure. Compounds with the piperazine scaffold exhibited the
best inhibitory activity among the initial compounds tested, with
compound a4 being the most potent inhibitor (IC =3.07 µM)
(Table 3). In order to enhance inhibition, He et al. crystallized
Compound b3 (IC = 5.16 µM), containing a piperidine with InhA
and NADH and that structure was used as a reference for future
compounds. The key hydrogen bond seen in all enoyl reductase
inhibition reactions, involving the catalytic residue Tyr158 was observed in the structure.The carbonyl oxygen of the arylamide was
hydrogen bonded to both the 2’-hydroxyl moiety of the nicotinamide ribose and to the hydroxyl group of Tyr158. The unsubstituted B ring fit into the substrate binding pocket and interacted
with many hydrophobic residues there. However, underneath the
B ring, extra space was observed (Figure 8). He et al. hypothesized
that addition of hydrophobic substituents to the B ring could form
more interactions and lead to higher affinity (He et al., 2007).

Table 3

The most potent inhibitors found by He et al. using High Throughput Screening

Compound

X

N

R1

R2

IC 5((µM)

a4

N

0

4-CH3

3-Cl

3.07 ± 0.48

b3

C

1

4-CH3

H

5.16 ± 0.45

He et al., 2007
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Table 4

Inhibition activity of newly synthesized arylamides

p1

99

0.4±0.02

p2

97

0.09±0.00

p3

94

0.2±0.01

p4

84

1.04±0.04

He et al., 2007

A variety of arylamides containing the piperazine scaffold were
synthesized. 12 of the 60 compounds synthesized showed high
InhA inhibitory activity. All 12 contained large polyaromatic moieties on the B ring, substantiating the hypothesis that larger substituents on the B ring form more interactions and lead to higher
affinity. Compound p2 (Table 4) of the newly synthesized molecules showed the highest inhibitory activity (IC = 90 nM), a 34 fold
decrease in IC when compared to compound a4, the most potent
of the HTS compounds (He et al., 2007).
Unfortunately, when the new compounds were tested against the
H37Rv strain for anti-tubercular activity, most had MIC values
>125 µM (He et al., 2007). This data suggests that the inhibitors
do not possess optimal membrane permeability, likely due to their
amphiphilicity, caused by the hydrophobicity of the B ring substituents and simultaneous hydrophilicity of the potentially protonated
C ring piperazine.

Figure 9
Compound p2, the most potent arylamide inhibitor synthesized by He et
al. (yellow) with NADH (purple) in the InhA substrate binding site. The rigid
residues around the binding site are displayed in green, while the flexible
residues are displayed in orange. As discussed, the A ring of the arylamide is
situated near the rigid residues, while the B ring is near the flexible residues.
Punkvang et al., 2010
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Figure 10a
Structure of the substrate analog, trans-2-hexadecenoyl-(N-acetylcysteamine)thioester Punkvang et al., 2010

Figure 10b
Superimposition of x-ray structures of compound p3, an arylamide inhibitor
synthesized by He et al. (pink) and fatty acid substrate (purple) in the InhA
substrate binding site. As discussed, the A ring binds to the hydrophilic part of
the binding site where the acetylcysteamine moiety of the substrate binds.The
B ring is shown to bind to the hydrophobic part of the binding site where the
fatty acid chain of the substrate binds. Punkvang et al., 2010

Punkvang et al. (2010) attempted to identify the reasons behind
the suboptimal anti-tubercular activity of the arylamides and to
propose modifications to the compounds to increase both their
affinity for InhA and anti-tubercular activity. Using molecular dynamics, a computer simulation that mathematically predicts the
physical movements of atoms and molecules, they investigated the
structural features and dynamic behavior of the InhA-inhibitor
interactions providing detailed information about the molecule’s
flexibility and conformation. RMSF (root mean square fluctuation)
of residues around the substrate binding site of InhA was calculated to reveal the mobile flexibility of the residues. Residues
96-99, 155-165, and 192-200 (located around the binding pocket
of the aryl A ring of the arylamide) were shown to be too rigid
to bind the arylamide inhibitors (Figure 9). In contrast, most of
the residues around the aryl B ring binding pocket (100-104, 149154, 201-223) indicated greater flexibility consistent with He et
al.’s proposal that additional large substituents can be added to
the B ring to increase the number of hydrophobic interactions
(Punkvang et al., 2010).
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Crystal structures and subsequent kinetic studies identify arylamides as competitive inhibitors of the substrate binding site
of InhA. Consequently, arylamides should mimic the binding of
the substrate. Superimposition of arylamide inhibitors bound to
InhA and a substrate analog (trans-2-hexadecenoyl-(N-acetylcysteamine)-thioester) (Figure 10a) bound to InhA shows the
conformational change that occurs in the enzyme when the arylamide or the substrate bind. It was observed that the A ring of
the arylamide binds to the hydrophilic part of the pocket where
the hydrophilic acetylcysteamine moiety of the substrate binds. In
contrast, the B ring lies in the same site as the fatty acyl chain of
the substrate surrounded by flexible hydrophobic residues (Figure
10b). The hydrophilic A ring is favored in the hydrophilic site and
the hydrophobic B ring substituent is favored in the area with the
hydrophobic residues (Punkvang et al., 2010).
Based on this data, Punkvang et al. proposed a series of modifications to the arylamides to mimic substrate binding and increase
inhibitory activity. Introduction of small hydrophilic substituents
such as an NH moiety or an acetyl oxygen on the A ring can be
used to mimic the analogous part of the substrate and increase
the hydrophilicity of the ring. Care must be taken, however, to
ensure that the substituents are not too large and do not lead to
steric interactions with the inflexible A ring residues and preclude
proper binding as discussed. Additionally, binding affinity of arylamides can be increased with the addition of bulky hydrophobic
substituents to the B ring (Punkvang et al., 2010).
These results explained the findings of He et al. and led to suggested future modifications of arylamides that may increase their
inhibitory potency. Molecular dynamic simulations showed that
only the hydrophobic part of the substrate binding pocket is flexible enough to bind arylamide inhibitors. Therefore, the addition

Figure 11
Pyridomycin structure Hartkoorn et al., 2012
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of bulky hydrophobic substituents on the B ring can increase the
binding affinity for the arylamides and also potentially increase
membrane permeability. More research is needed to synthesize
these proposed compounds and to measure their InhA inhibitory
properties as well as their anti-tubercular properties and to see if
membrane permeability indeed increased.

Pyridomycin

Discovered in 1953, pyridomycin (Figure 11) is a natural antibiotic produced by the bacteria Streptomyces pyridomyceticus and
Dactylosporangium fulvum that exhibits specific activity against
Mycobacteria (Maeda et al., 1953). Nevertheless, since it was only
discovered a short time after the introduction of isoniazid as an
exceedingly effective treatment for tuberculosis, pyridomycin was
neglected and research into the drug ceased. Presently, with the
rise of INH-resistant strains of TB, it is imperative to reexamine
effective alternatives to INH. Despite earlier reports of pyridomycin’s effectiveness against Mycobacteria as a genus, its efficacy
against M. tuberculosis specifically had not yet been completely
demonstrated. Additionally, pyridomycin’s target and mechanism
of action had also not yet been elucidated. Hartkoorn et al. (2012)
ascertained the drug’s target and specificity, and assessed its efficacy against TB.
Pyridomycin was tested to confirm earlier reports about its specificity, efficacy, and low toxicity. The new research showed pyridomycin to be a competent inhibitor of all species of Mycobacteria
including tuberculosis (MIC= 0.62-1.25 µg/ml). It remained ineffective against other genera of both gram positive and gram negative classification (MIC > 100 µg/ml), confirming its specificity
to a feature unique to Mycobacteria. It effectiveness against TBinfected THP-1 derived macrophages was verified which indicated its ability to physically enter macrophages and inhibit growth.
Toxicity testing demonstrated pyridomycin’s higher selectivity for
tuberculosis than for human cells with a selectivity index of >100fold. (Hartkoorn et al., 2012)
The identity of the target of pyridomycin was obtained by selecting for mutant pyridomycin-resistant strains (PYR7) on solid medium containing pyridomycin at 10xMIC (3µg/ml). The genome of
mutant PYR7 was referenced to H37Rv (wild type strain) and an
a443g point mutation in InhA was isolated in PYR7 which resulted
in replacement of the aspartic acid at position 148 by a glycine
(D148G). Asp148 was previously identified in the binding pocket
of InhA thus validating this as pyridomycins’s target. Subsequent
experiments involving overexpression of InhA and the resulting
increase in pyridomycin resistance further confirmed these findings (Hartkoorn et al., 2012).
Since the primary goal of research into pyridomycin was to determine its potential as an alternative to isoniazid, pyridomycin
was tested against INH-resistant strains of TB. KatG mutants

Figure 12
Binding comparison of various InhA inhibitors.The blue area represents the lipid
substrate binding pocket, while the red area represents the NADH binding site.
a) The lipid substrate is bound to the substrate binding site. b) Triclosan
derivatives have all been shown to bind solely to the substrate binding site. c)
The INH-NAD adduct binds solely to the NADH binding site. d) Pyridomycin
binds to the NADH binding site and, because of its large size, extends into the
lipid substrate binding site as well. Hartkoorn et al., 2014

(the majority of the resistant strains), despite being highly resistant to INH (MIC >10 µg/ml), showed no resistance to pyridomycin. This demonstrated that pyridomycin does not depend on
catalase-peroxidase bioactivation and therefore holds increased
potential for use against the more common KatG INH-resistant
strain (Hartkoorn et al., 2012). The results of this research confirmed previous reports of pyridomycin’s selectivity for and efficacy against tuberculosis including H37Rv and INH-resistant strains.
As discussed earlier, InhA contains two essential sites: the NADH
binding site and the lipid substrate binding pocket. Crystal
structures and kinetic experimentation show that pyridomycin
is a direct competitive inhibitor of NADH binding in InhA and
occupies the NADH binding site. Pyridomycin forms several interactions with residues in the NADH binding site including the
crucial hydrogen bond between the side chain of Tyr158 and the
C7 carbonyl oxygen of pyridomycin. Loss of this hydrogen bond
and consequent lack of the crucial enoyl reductase-inhibitor interaction in D148G mutants (pyridomycin-resistant InhA) resulted
in markedly decreased affinity for pyridomycin. Crystal structures
show that, as a result of its unusually large size, pyridomycin not
only occupies the NADH binding site, but its upper hemisphere
also extends into the substrate binding pocket forming a hydrophobic interaction with Phe149. While previously identified InhA
inhibitors exclusively inhibited only one of the sites, pyridomycin
is the first published compound to bridge the gap between both
sites and simultaneously inhibit the lipid substrate binding pocket
as well as the NADH binding site (Figure 12) (Hartkoorn et al.,
2014).
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Pyridomycin is a naturally produced antibiotic and efforts to synthesize it have been hampered by the inability to form the double
bond of the enol ester moiety between C1 and C2. The compound was instead synthesized with a saturation in that position
(and a replacement of the sec-butyl group with a symmetrical isopropyl group) to identify if the double bond was indeed necessary
for anti-tubercular activity. Saturation generated a new stereocenter, producing two stereoisomers: the R isomer (OH141) and
the S isomer (OH139) (Figure 13). Both compounds, as well as
natural pyridomycin were then tested for anti-tubercular activity.
Pyridomycin was the most effective against TB (MIC = 0.39 µg/ml).
OH139 had a MIC value 32-fold higher than pyridomycin while
OH141 measured only 4-fold higher, indicating that the enol ester
moiety is not actually a critical requirement for anti-TB activity
(Horlacher et al., 2013).

Figure 13
Pyridomycin (1) and the newly synthesized compounds (2,3) with a saturation
in the C1-C2 bond and replacement of the sec-butyl group with an isopropyl
group. A new stereocenter led to the production of two stereoisomers: the R
isomer (OH141) and the S isomer (OH139). Horlacher et al., 2013

X-ray crystallography and in silico modeling highlight the reasoning
behind the difference in efficacy between the two stereoisomers.
Superposition of InhA:pyr on InhA:OH141 show pyridomycin and
OH141 occupying the same position in the active site.The isopropyl
group of OH141 was found in the equatorial position avoiding any
steric clashes with residues in the active site. OH139 however, was
shown with its isopropyl group in a steric interaction with the side
chain of Met199 in the substrate binding loop, indicating why OH139
has a lower affinity for InhA than does OH141 (Horlacher et al.,
2013).The slight decrease in the activity of OH141 compared to pyridomycin could be due to the lower hydrophobicity of the isopropyl
group compared to the 2-butan-2-ylidene substituent.The results of
this research demonstrate that pyridomycin can be synthesized with
a saturation in the C1-C2 bond without significantly impacting its
anti-tubercular activity. This establishes the potential for future SAR
work in the development of pyridomycin-derived drug candidates
for TB treatment. Current research is now focused on using OH141
as a scaffold for synthesis of new pyridomycin variants.
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Conclusion

In this review, SAR has been shown to be an effective means to
structurally design and modify drugs to increase their InhA inhibition abilities. The underlying assumption of the research was
that compounds that do not require KatG activation would be effective against most INH-resistant strains. This hypothesis proved
correct in the case of triclosan and pyridomycin derivatives.
Additional modifications to arylamides are needed to optimize
their activity. Through analysis of crystal structures, along with
computer-assisted molecular dynamics and modeling, a variety
of high affinity compounds were synthesized. Current efforts are
now concentrated on optimizing the in vivo properties of these
novel compounds.

Abbreviations

TB		 Tuberculosis
MDR-TB
Multi Drug Resistant Tuberculosis
XDR-TB		
Extensively Drug Resistant Tuberculosis
INH		
Isoniazid
SAR		
Structure Activity Relationship
IC50		
Half maximal inhibitory concentration (the concentration of inhibitor at which half of the enzymes are inhibited)
K i 		
Inhibitory constant
MIC		
Minimum Inhibitory Concentration
H37Rv		
Wild type strain of TB
cLogP		
Calculated partition coefficient
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